EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CRISPR-Cas–Mediated Precision Antimicrobial Strategies for Targeting Multidrug-Resistant Bacteria: Mechanisms, Delivery Systems, and Clinical Potential

Muqaddas Noor, Hakmeen Khawaja, Adnan Khan, Muhammad Nauman Sharif, Nimra Ramzan, Ayesha Jamshaid

Global Research Journal of Natural Science and Technology · 15.04.2026

DOI: 10.53762/grjnst.04.02.13 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Research Journal of Natural Science and Technology, online erschienen am 15.04.2026. Verfasst von Muqaddas Noor und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The escalating crisis of antimicrobial resistance (AMR) has outpaced conventional antibiotic discovery, necessitating innovative, sequence-specific therapeutic modalities. This review critically evaluates CRISPR-Cas–mediated antimicrobial strategies as a programmable alternative for eradicating multidrug-resistant (MDR) bacterial pathogens. We synthesize current evidence on mechanistic platforms, including DNA/RNA-targeting nucleases (Cas9, Cas12a, Cas13) and transcriptional modulators (CRISPRi/a), highlighting their capacity for precise pathogen elimination, resistance plasmid curing, and antibiotic resensitization. Furthermore, we assess emerging delivery architectures, engineered bacteriophages, lipid nanoparticles, and conjugative plasmids, detailing their tropism specificity, payload stability, and in vivo pharmacokinetic profiles. Despite robust preclinical efficacy and microbiome-sparing advantages, clinical translation remains constrained by delivery inefficiencies in complex host environments, bacterial counter-adaptations (e.g., anti-CRISPR proteins, PAM mutations), and the absence of standardized regulatory and pharmacological frameworks. We propose actionable recommendations for effector multiplexing, adaptive clinical trial design, GMP-scale manufacturing, and One Health–aligned ecological stewardship. CRISPR-Cas antimicrobials represent a transformative frontier in infectious disease therapeutics; realizing their clinical potential demands interdisciplinary convergence, regulatory modernization, and rigorous translational validation to safeguard global health in the post-antibiotic era.

Zitieren

APA

Noor, M., Khawaja, H., Khan, A., Sharif, M. N., Ramzan, N., & Jamshaid, A. (2026). CRISPR-Cas–Mediated Precision Antimicrobial Strategies for Targeting Multidrug-Resistant Bacteria: Mechanisms, Delivery Systems, and Clinical Potential. Global Research Journal of Natural Science and Technology. https://doi.org/10.53762/grjnst.04.02.13

Vancouver

Noor M, Khawaja H, Khan A, Sharif MN, Ramzan N, Jamshaid A. CRISPR-Cas–Mediated Precision Antimicrobial Strategies for Targeting Multidrug-Resistant Bacteria: Mechanisms, Delivery Systems, and Clinical Potential. Global Research Journal of Natural Science and Technology. 2026. doi:10.53762/grjnst.04.02.13

BibTeX
@article{Noor2026,
  author = {Noor, Muqaddas and Khawaja, Hakmeen and Khan, Adnan and Sharif, Muhammad Nauman and Ramzan, Nimra and Jamshaid, Ayesha},
  title = {CRISPR-Cas–Mediated Precision Antimicrobial Strategies for Targeting Multidrug-Resistant Bacteria: Mechanisms, Delivery Systems, and Clinical Potential},
  journal = {Global Research Journal of Natural Science and Technology},
  year = {2026},
  doi = {10.53762/grjnst.04.02.13}
}
Kostenlos starten →